Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

Lexeo Therapeutics' abstract for LX2006, its AAV-based gene therapy for Friedreich ataxia, was accepted for an oral presentation at the MDS 2026 congress in Seoul on October 7. The presentation will highlight previously reported early stabilization or improvement in mFARS scores versus a propensity-matched natural history control cohort, plus new mFARS subscore analyses. LX2006 is in a Phase 2 registrational trial (SUNRISE-FA 2) and holds FDA Breakthrough Therapy and multiple other designations; the congress slot adds visibility but no new efficacy readout.

•1mo ago

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

Lexeo Therapeutics gained access to Apertura Gene Therapy's TfR1 CapX, an IV-delivered AAV capsid designed to cross the blood-brain barrier, for a program targeting Friedreich ataxia. The agreement expands Lexeo's toolkit beyond its clinical candidate LX2006, with CFO Louis Tamayo citing the potential for a less invasive CNS route of administration following initial systemic dosing. No financial terms were disclosed, and the capsid application remains at the research/evaluation stage, limiting near-term impact.

•1mo ago

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Lexeo Therapeutics signed a definitive agreement to acquire privately held Mantle Therapeutics for $8.3 million upfront in a combination of cash and equity, with up to $13.0 million more payable on clinical and regulatory milestones, bringing total potential consideration to $21.3 million; closing is expected in the third quarter of 2026. The acquisition adds four Friedreich ataxia programs: clinical-stage oral combination therapy LX3010, which showed an approximately 6-point mFARS improvement at 16 weeks and a mean nine-fold increase in frataxin protein in muscle biopsies across 11 FA patients, plus preclinical candidates LX3030 and LX3050 and discovery-stage LX3070. Lexeo also launched three collaborations supporting cerebellar-targeted sequential dosing of its gene therapy LX2006: a sponsored research agreement with Weill Cornell Medicine, an option agreement with Vivet Therapeutics for the IgG-degrading enzyme VTX-PID, and an option with Apertura Gene Therapy for the blood-brain barrier-crossing CapX capsid. The SUNRISE-FA 2 pivotal study of LX2006 remains the company's top priority with topline data on track for the second half of 2027, and cash runway guidance is unchanged into 2028, with one acquired program planned to enter clinical development.

•1mo ago

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo reported a Q2 net loss of $0.30 per share, with R&D expenses increasing to $19.0 million as the company advanced its pipeline, ending the quarter with a strong cash position of $234.2 million expected to fund operations into 2028. Operationally, the company initiated the pivotal SUNRISE-FA 2 trial for LX2006 in Friedreich ataxia cardiomyopathy in June, with topline data anticipated in the second half of 2027. Additionally, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy, a milestone that should expedite development and increase FDA interaction.

•2mo ago

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020, an investigational gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. The designation was granted based on interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial, marking the third FDA designation for LX2020 alongside Orphan Drug and Fast Track status. PKP2 mutations affect approximately 60,000 people in the U.S. and are responsible for about 50% of ACM cases, representing a significant unmet medical need with no current approved disease-modifying treatments.

•2mo ago

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Lexeo Therapeutics announced the publication of Phase I/II data for its gene therapy LX2006 in JAMA Cardiology, showing the treatment was generally well-tolerated with early signs of efficacy in Friedreich ataxia. Data from 17 participants demonstrated mean improvements in Left Ventricular Mass Index (LVMI) of 28% at 6 months and 33% at 12 months in mid- and high-dose cohorts, alongside improvements in cardiac biomarkers and frataxin expression. The company confirmed the pivotal SUNRISE-FA 2 study remains on track to initiate by the end of June 2026, with topline data expected in the second half of 2027.

•4mo ago

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Lexeo Therapeutics has finalized the protocol and statistical analysis plan for SUNRISE-FA 2, the pivotal trial for its gene therapy candidate LX2006 in Friedreich ataxia cardiomyopathy. The study utilizes an open-label design with 13 treated patients and 13 untreated controls, avoiding a placebo arm. The primary endpoint is Left Ventricular Mass Index (LVMI) assessed via MRI at 6 months, with the FDA having removed the cardiac frataxin protein expression co-primary endpoint. Lexeo expects to enroll the first patient by the end of June 2026, with topline data in H2 2027 and a Biologics License Application (BLA) submission under the accelerated approval pathway in H1 2028.

•4mo ago